Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 3, 2016, Pages 456-461

  Patel, Khilna ^a   Parmar, Sapna ^a   Shah, Shreya ^a   Shore, Tsiporah ^a   Gergis, Usama ^a   Mayer, Sebastian ^a   van Besien, Koen ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Infusion related reactions; Intravenous alemtuzumab; Subcutaneous alemtuzumab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; DIPHENHYDRAMINE; FILGRASTIM; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; LEVOFLOXACIN; MELPHALAN; MYCOPHENOLATE MOFETIL; PARACETAMOL; RAPAMYCIN; TACROLIMUS; VALACICLOVIR; VORICONAZOLE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ARTICLE; BACTEREMIA; BRONCHOSPASM; CHILL; CLINICAL ARTICLE; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; DYSPNEA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; INFECTION; INFUSION RELATED REACTION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RECURRENCE RISK; RETROSPECTIVE STUDY; RIGOR; SURVIVAL RATE; UNRELATED DONORS; URTICARIA; VIREMIA; VIRUS REACTIVATION; ALLOGRAFT; ANALOGS AND DERIVATIVES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSPLANTATION CONDITIONING;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ALLOGRAFTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MELPHALAN; MIDDLE AGED; TRANSPLANTATION CONDITIONING; UNRELATED DONORS; VIDARABINE;

EID: 84951997856     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.022     Document Type: Article

References (16)

1. 1 Hu, Y., Turner, M.J., Shields, J., et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128 (2009), 260–270.
2. 2 Perez-Simon, J.A., Kottaridis, P.D., Martino, R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002), 3121–3127.
3. 3 van Besien, K., Kunavakkam, R., Rondon, G., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15 (2009), 610–617.
4. 4 Soiffer, R.J., Lerademacher, J., Ho, V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117 (2011), 6963–6970.
5. 5 Poire, X., van Besien, K., Alemtuzumab in allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11 (2011), 1099–1111.
6. 6 Ferrajoli, A., O'Brien, S.M., Cortes, J.E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98 (2003), 773–778.
7. 7 Kottaridis, P.D., Milligan, D.W., Chopra, R., et al. In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000), 2419–2425.
8. 8 Kline, J., Pollyea, D.A., van Besien, K., et al. Pre-transplant ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 37 (2006), 307–310.
9. 9 Przepiorka, D., Weisdorf, D., Martin, P., et al. 1994 Consensus conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
10. 10 Filipovich, A.H., Weisdorf, D.W., Pavletic, S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005), 945–955.
11. 11 Sorror, M.L., Maris, M.B., Storer, B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104 (2004), 961–968.
12. 12 Marsh, R.A., Rao, M.B., Gefen, A., et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant 21 (2015), 1460–1470.
13. 13 Lundin, J., Kimby, E., Bjorkholm, M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (BCLL). Blood 100 (2002), 768–773.
14. 14 Dearden, C., Khot, A., Else, M., et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118 (2011), 5799–5802.
15. 15 Hale, G., Rebello, P., Brettman, L.R., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004), 948–955.
16. 16 Montagna, M., Montillo, M., Avanzini, M.A., et al. Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica 96 (2011), 932–936.